2026-10-25
Zimmer Biomet clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,946 −5.25%
S&P 7,428 −3.39%
GOLD $4,132 +1.46%
BTC $75,633 −5.94%
VIX 23.84 +43.53%
latest tape · as of 18:03 UTC
The Screen · Healthcare · Medical Devices
Zimmer Biomet
ZBH · a US exchange · USD · Market cap $18.0B · 17,000 employees
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
Not yet scored110.15 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 18:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price110.15 USD at the 4 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 4 Nov 2026
- Our regime readMarkup, as of 4 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.02)
- Last reviewed4 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $130.00 to $194.12, base estimate $130.00 (screen dated 2026-11-04).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning political selling, disclosed 2026-09-14
- Options put/call open interest 0.02, read 2026-11-05
- Ethical screen not yet scored
Price110.15 USD
Fair value130.00
Ethical score85.2/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-21Read Markup94.98+16.0% to today ✓Distribution gives way to Markup first Markup read since August
2026-09-18Read Distribution94.61+16.4% to today Markup gives way to Distribution first Distribution read since July
2026-08-19Read Markup97.19+13.3% to today ✓Distribution gives way to Markup after an 11% rise in 7 weeks
2026-07-02Read Distribution87.33+26.1% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
Zimmer Biomet holds its Markup at $110.15. Consolidating, no directional conviction, held for 52 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 52 days |
| Price at the screen | $110.15 |
| Valuation | 22.94 trailing · 10.44 forward price to earnings |
| Values screen | Not scored · score 85.2 |
| Beta | 0.49 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 32.56% | Below 33% | Interest-bearing debt is just 32.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 9.94% | Below 49% | Money owed to the company is 9.9% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Zimmer Biomet clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Zimmer Biomet clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 33%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 25% discount to our $130.00 fair value, narrow competitive moat, 4.80% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 15.3% discount to the base estimate.
Third-party analyst targets: 21 covering, consensus Buy. The average target sits −5% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & ProjectionsWhere our models see it going: fair-value estimate $130.00, with a range of $130.00 to $194.12, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsNew hips and knees meet steady demand
When a patient finally gets a new knee after years of pain the implant must fit exactly and last for decades. Zimmer Biomet designs and sells those devices worldwide.
The company grows revenue 9 percent a year and trades on a forward P/E of 10.1 times with a 30 percent margin of safety to fair value. It clears the ethical screen and holds a narrow moat in reconstructive orthopaedics.
Return on equity sits at just 6 percent and profit margins are 9 percent, so any slowdown in elective procedures or rise in competition would quickly pressure results. Analyst targets cluster near current prices.
Analysis, not advice.
| Forward P/E | 10.4xexpensive even after accounting for its growth |
| Trailing P/E | 22.9xa premium valuation |
| EPS, trailing | 4.12 |
| EPS, forward | 9.05 |
| Revenue growth | +4.8%slow but positive growth |
| Profit margin | 9.5%thin but positive margins |
| Return on equity | 6.4%a modest return on shareholder capital |
| FCF yield | 5.95% |
| Dividend yield | 1.16% |
| Debt to equity | 0.60moderate, manageable leverage |
| Current ratio | 1.69healthy short-term liquidity |
| Beta | 0.49barely tracks the market's swings |
| Short interest, float | 0.06% |
| 52-week range | 79.12 - 103.70 |
| Moat | NARROW |
| Market cap | $18.0B |
| Employees | 17,000 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeZBH trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-04
Markup $97.06
+2.7% Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03
Markup $94.52
+0.0% Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02
Markup $94.52
+0.0% Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01
Markup $94.52
+0.0% Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Markup $94.52
-4.1% Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Markup $98.56
+0.0% Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Markup $98.56
+3.8% Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28
Markup $94.98
+0.0% Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Markup · changed $94.98
+6.6% Entry 8
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99.
2026-10-14
Distribution $89.14
-2.7% Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Zimmer Biomet (ZBH) Stock May Be A Bargain Despite Robot Surgery Push Yahoo Finance · 6d ago
- Stryker Sinks 5% on Q3 Miss and Guidance Cut: “Fall Short of Our Expectations” Yahoo Finance · 6d ago
- Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards? Yahoo Finance · 7d ago
- Zimmer Biomet to Preview the Next Era of Intelligent Orthopedic Surgery at AAHKS 2026 Yahoo Finance · 7d ago
- Is Intuitive Surgical Stock's Market Price Justified? Yahoo Finance · 7d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
STESteris
PHGKoninklijke Philips NV ADR
PENPenumbra Inc
SNNSmith & Nephew plc ADR
GMEDGlobus Medical Inc
GEHCGE HealthCare
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | NOOR JEHANZEB | Officer | 6,626 | · | |
| 2026-03-12 | WINKLER LORI | Officer | 2,650 | $250,849 | |
| 2026-03-06 | UPADHYAY SUKETU P | Chief Financial Officer | 14,776 | · | |
| 2026-03-06 | PHIPPS CHAD F | Officer | 6,786 | · | |
| 2026-03-06 | WINKLER LORI | Officer | 5,634 | · | |
| 2026-03-06 | VAN ZUILEN WILFRED | Officer | 7,004 | · | |
| 2026-03-06 | YI SANG | Officer | 9,414 | · | |
| 2026-03-06 | STELLATO PAUL A | Officer | 1,970 | · | |
| 2026-03-06 | TORNOS IVAN | Chief Executive Officer | 34,704 | · | |
| 2026-02-25 | UPADHYAY SUKETU P | Chief Financial Officer | 6,364 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-14 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-14 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-14 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-14 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-14 | Ro Khanna | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $79.58 | +10.8% | · | $1,108 | +10.8% |
| 2 months | $93.12 | -5.3% | · | $947 | -5.3% |
| 3 months | $92.34 | -4.5% | $0.24 | $957 | -4.3% |
| 6 months | $91.96 | -4.1% | $0.48 | $964 | -3.6% |
| 1 year | $93.94 | -6.1% | $0.96 | $949 | -5.1% |
| 2 years | $110.73 | -20.4% | $1.92 | $814 | -18.6% |
| 3 years | $132.40 | -33.4% | $2.88 | $688 | -31.2% |
| 5 years | $147.34 | -40.2% | $4.78 | $631 | -36.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ZBH does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.